Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
Transcript
Are there any novel therapies currently being researched by your division for gynecologic malignancies?
Our division at Stanford in gynecologic oncology is very interested in pushing and investigating very innovative therapies. We have a particular focus on immunotherapies. Immunotherapies can be very diverse. Immune checkpoint inhibitors, as they have been approved, are still being investigated in clinical trials, in particular, in combination with chemotherapy or other immunostimulant drugs.
I’m very excited about cell therapies that allow us to use the body’s own white blood cells, or the patient’s own white blood cells, to potentially create antitumor effects. So, these white blood cells they’re taking out of the patients, they’re potentially genetically modified, so they recognize the tumor. They are then being reinfused, and hopefully recognize the tumor and have antitumor effects.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More